Generic Name and Formulations:
Isoniazid 300mg; scored tabs.
Various generic manufacturers
Indications for Isoniazid:
Prophylaxis and treatment of susceptible tuberculosis.
Prophylaxis: 300mg once daily. Active infection: 5mg/kg daily; max 300mg once daily. Do not interrupt therapy.
Prophylaxis: 10mg/kg once daily; max 300mg daily. Active infection: 10–20mg/kg once daily; max 500mg daily. Do not interrupt therapy.
Drug-induced hepatitis. Previous isoniazid-associated hepatic injury. Severe adverse reactions to isoniazid (eg, drug fever, chills, arthritis). Acute liver disease of any etiology.
Impaired renal or hepatic function. Monitor hepatic and ocular function. Alcoholism. Diabetes. Increased risk of liver damage with increasing age. Multiple drug therapy and concomitant pyridoxine may be necessary. Pregnancy. Nursing mothers.
Potentiates phenytoin. Alcohol increases risk of hepatitis. Pyridoxine deficiency increases risk of neuropathy.
Peripheral neuropathy (esp. in slow acetylators), elevated serum transaminases (SGOT; SGPT), bilirubinemia, bilirubinuria, jaundice, hepatitis (may be fatal), nausea, vomiting, epigastric distress, pancreatitis, blood dyscrasias, hypersensitivity reactions (eg, skin eruptions, TEN, DRESS), pyridoxine deficiency, hyperglycemia, pellagra, metabolic acidosis, gynecomastia, rheumatic syndrome, SLE-like syndrome.
Formerly known under the brand names INH, Laniazid.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Examining the Efficacy of Different Oxygen Flow Rates for Cluster Headache Attacks
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- Daily Alcohol Use May Drive Chronic Pain in Adults With HIV
- Tools to Address the Opioid Crisis
- AHA/ACC Release Updated Guidelines for Cholesterol Management
- Women Fed Soy Formula as Infants More Likely to Experience Menstrual Pain